CN106310023A - Drug for treating small cell lung cancer, and preparation method and application thereof - Google Patents
Drug for treating small cell lung cancer, and preparation method and application thereof Download PDFInfo
- Publication number
- CN106310023A CN106310023A CN201610991813.0A CN201610991813A CN106310023A CN 106310023 A CN106310023 A CN 106310023A CN 201610991813 A CN201610991813 A CN 201610991813A CN 106310023 A CN106310023 A CN 106310023A
- Authority
- CN
- China
- Prior art keywords
- extract
- medicine
- small cell
- lung cancer
- cell lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 95
- 206010041067 Small cell lung cancer Diseases 0.000 title claims abstract description 54
- 208000000587 small cell lung carcinoma Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 272
- 241000190633 Cordyceps Species 0.000 claims abstract description 25
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 21
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 19
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000011669 selenium Substances 0.000 claims abstract description 9
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 53
- 241000180649 Panax notoginseng Species 0.000 claims description 21
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 21
- 241000756943 Codonopsis Species 0.000 claims description 19
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 19
- 241001313857 Bletilla striata Species 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 7
- 229920001525 carrageenan Polymers 0.000 abstract description 3
- 239000000679 carrageenan Substances 0.000 abstract description 3
- 229940113118 carrageenan Drugs 0.000 abstract description 3
- 235000010418 carrageenan Nutrition 0.000 abstract description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241001313855 Bletilla Species 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 abstract 1
- 229940067866 dandelion extract Drugs 0.000 abstract 1
- 235000020691 dandelion extract Nutrition 0.000 abstract 1
- 229940069445 licorice extract Drugs 0.000 abstract 1
- 239000001845 taraxacum officinale leaf extract Substances 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 231100000614 poison Toxicity 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 230000001093 anti-cancer Effects 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 11
- 239000003440 toxic substance Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 206010027336 Menstruation delayed Diseases 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000001788 irregular Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241001061264 Astragalus Species 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 210000004233 talus Anatomy 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside Rg2 Natural products O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241001674343 Taxus x media Species 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical compound C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 241000544045 Cymodocea nodosa Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010065873 Pulmonary fistula Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010061577 Ulcer haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- GHKISGDRQRSCII-UHFFFAOYSA-N chelidonine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 229930189271 taxine Natural products 0.000 description 1
- -1 taxine diterpene compound Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a drug for treating small cell lung cancer, and a preparation method and an application thereof and relates to the technical field of a traditional Chinese medicine. The drug for treating small cell lung cancer comprises the following raw materials: 0.5-1 part of Chinese yew extract, 0.2-0.6 part of manyleaf paris rhizome extract, 0.3-1.5 parts of ginseng extract, 1.2-1.5 parts of hedyotis diffusa extract, 1.2-1.5 parts of semen coicis extract, 0.1-0.5 part of dandelion extract, 0.8-1.0 part of astragalus membranaceus extract, 0.2-0.5 part of celandine extract, 0.2-0.4 part of bletilla extract, 0.2-0.5 part of rhizoma podophylli emodi extract, 0.6-0.9 part of conch extract, 0.2-0.4 part of licorice extract, 0.1-0.4 part of pseudo-ginseng extract, 0.2-0.8 part of angelica sinensis extract, 0.8-1.0 part of date extract, 0.6-0.9 part of cordyceps extract and 0.005-0.02 part of selenium carrageenan.
Description
Technical field
The present invention relates to technical field of Chinese medicines, especially relate to a kind of treat the medicine of small cell lung cancer, preparation method and
Its purposes.
Background technology
In recent years, the sickness rate of the small cell lung cancer in pulmonary carcinoma is in rising trend, and tends to rejuvenation.Small cell lung cancer
Clinical symptoms be persistency cough, uncomfortable in chest, sputum mixed with blood silk, breathe hard, low and deep, heating, weak, become thin, sign has lock
Bone superior gluteal lymph node enlargement, and brain metastes feature is more, one it is found that belong to late period.
The symptoms such as " pulmonary fistula ", " cough " at Chinese medical book, it is seen that with the clinical symptom group that pulmonary carcinoma is similar, its pathogenesis is
Six climate exopathogens exopathogen, interior model are in lung.Or disease poison become silted up evil, interior tie in lung, stop mechanism of qi, declare respectful mistake department, the lung pulse become silted up resistance, phlegm-damp not flower, become silted up
In poison, knot, healthy energy consume, internal organs consume, negative and positive all lose institute extremely.Tcm treatment according to syndrome differentiation, can use benefiting QI and nourishing blood, strengthening spleen, tonifying kidney, work
Blood blood stasis dispelling, the method for the toxin expelling that eliminates the phlegm.
Owing to the developing small cell lung cancer in late period is fast, intractable greatly, had a strong impact on physical rehabilitation and the life matter of patient
Amount, brings great misery to patient.Current medicine is difficult to suppression successive elimination cancerous cell, and therefore, evening is treated in research
The medicine of phase small cell lung cancer, necessary.
In view of this, the special proposition present invention.
Summary of the invention
The first object of the present invention is to provide a kind of medicine treating small cell lung cancer, to solve medicine of the prior art
Thing therapeutic effect is poor, the technical problem of the length course for the treatment of.
The second object of the present invention is to provide the preparation method of a kind of medicine treating small cell lung cancer, this preparation method
Have that technological process is simple and the advantage of applicable industrialized production.
In order to realize the above-mentioned purpose of the present invention, spy by the following technical solutions:
A kind of medicine treating small cell lung cancer, counts by weight and includes following raw material:
Ramulus et folium taxi cuspidatae Extract 0.5-1 part, Rhizoma Paridis extract 0.2-0.6 part, Radix Ginseng extract 0.3-1.5 part, Herba Hedyotidis Diffusae
Extract 1.2-1.5 part, Semen Coicis extract 1.2-1.5 part, Herba Taraxaci extract 0.1-0.5 part, Radix Astragali extract
0.8-1.0 part, Herba Chelidonii extract 0.2-0.5 part, bletilla striata extract 0.2-0.4 part, Rhizoma Dysosmae Versipellis extract 0.2-0.5 part,
Radix Codonopsis lanceolatae extract 0.6-0.9 part, Radix Glycyrrhizae extract 0.2-0.4 part, Radix Notoginseng extract 0.1-0.4 part, Radix Angelicae Sinensis extract
0.2-0.8 part, Fructus Jujubae extract 0.8-1.0 part, Cordyceps extract 0.6-0.9 part and selenocarrageenan 0.01 part.
Further, the medicine of above-mentioned treatment small cell lung cancer is counted by weight and is included following raw material:
Ramulus et folium taxi cuspidatae Extract 0.6-0.9 part, Rhizoma Paridis extract 0.3-0.5 part, Radix Ginseng extract 0.5-1.2 part, tang
Grass extract 1.3-1.5 part, Semen Coicis extract 1.3-1.5 part, Herba Taraxaci extract 0.2-0.4 part, Radix Astragali extract
0.9-1.0 part, Herba Chelidonii extract 0.3-0.4 part, bletilla striata extract 0.25-0.35 part, Rhizoma Dysosmae Versipellis extract 0.3-0.4
Part, Radix Codonopsis lanceolatae extract 0.7-0.9 part, Radix Glycyrrhizae extract 0.2-0.3 part, Radix Notoginseng extract 0.2-0.3 part, Radix Angelicae Sinensis extract
Thing 0.3-0.7 part, Fructus Jujubae extract 0.85-0.95 part, Cordyceps extract 0.7-0.9 part and selenocarrageenan 0.01 part.
Further, the medicine of above-mentioned treatment small cell lung cancer is counted by weight and is included following raw material:
Ramulus et folium taxi cuspidatae extracts concentrate 0.6 part, Rhizoma Paridis extracts concentrate 0.4 part, Radix Ginseng extracts concentrate 0.6 part, Herba Hedyotidis Diffusae
Extract concentrate 1.5 parts, Semen Coicis extracts concentrate 1.5 parts, Herba Taraxaci extracts concentrate 0.3 part, astragalus extraction concentrate 1.0
Part, Herba Chelidonii extract 0.3 part, the Pseudobulbus Bletillae (Rhizoma Bletillae) extract concentrate 0.3 part, Rhizoma Dysosmae Versipellis extraction concentrate 0.3 part, Radix Codonopsis lanceolatae extraction concentrate
0.9 part, Radix Glycyrrhizae extract concentrate 0.2 part, Radix Notoginseng extract concentrate 0.2 part, Radix Angelicae Sinensis extract concentrate 0.6 part, Fructus Jujubae extract dense
Contracting thing 0.9 part, Cordyceps extract concentrate 0.9 part, selenocarrageenan 0.01 part.
Further, in above-mentioned selenocarrageenan, the content of organic selenium is 3wt%.
The preparation method of the medicine of above-mentioned treatment small cell lung cancer, comprises the following steps:
Weigh above-mentioned raw materials medicine in container, put into after mix homogeneously in granulator and pelletize, obtain described treatment minicell
The medicine of pulmonary carcinoma.
Further, described pelletization uses spraying purified water pelletize.
Further, dry step is also included after pelletization.
Further, the step of sterilizing is also included after being dried.
Further, above-mentioned raw materials medicine is put in electronic mixing container, roll 1-5min, take out after mix homogeneously and put
Enter in electronic granulator, use spraying purified water pelletize, after drying by sterilization processing, be vacuum-packed and i.e. obtain described treatment minicell lung
The medicine of cancer.
Being prepared as graininess is to facilitate patient to take, and from the point of view of Chinese medicine, the most acceptable facilitates dosage form.
The medicine of above-mentioned treatment small cell lung cancer purposes in the medicine of preparation treatment small cell lung cancer.
Compared with the prior art, there is advantages that
The medicine of the treatment small cell lung cancer provided in the present invention, utilizes Ramulus et folium taxi cuspidatae and the significant antitumaous effect of selenium element former
Reason, the active substance Ramulus et folium taxi cuspidatae Extract grown by anti-cancer active matter and the anticancer of reasonably combined hepatocarcinoma and selenizing
Carrageenan, and scientific compatibility has the Herba Chelidonii extract of anti-cancer and kill cancer action, Rhizoma Dysosmae Versipellis extract and Radix Codonopsis lanceolatae extract, can have
The growth of cancerous cell in effect suppression minicell hepatocarcinoma, and produce certain forward improvement result to rising, cancerous cell can be induced normal
Change.Meanwhile, medicine Rhizoma Paridis extract that anti-inflammatory analgesic invigorates blood circulation, Herba Hedyotidis Diffusae extract, Herba Taraxaci extract, astragalus extraction it are equipped with
Thing, bletilla striata extract, Radix Glycyrrhizae extract, Radix Notoginseng extract, Radix Angelicae Sinensis extract and Cordyceps extract, can improve cancerous cell further
Growing environment, suppress Normocellular canceration.It addition, add again Radix Ginseng extract, Semen Coicis extract, Fructus Jujubae extract and
The nutrient substance such as Cordyceps extract, regulating human immunologic function and enhancing resistance against diseases, the regeneration of anticancer.Utilize this
The Drug therapy small cell lung cancer that invention provides has short treating period, good effect, instant effect and the advantage having no side effect.
Detailed description of the invention
Below in conjunction with embodiment, embodiment of the present invention are described in detail, but those skilled in the art will
Understanding, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the present invention.In embodiment unreceipted specifically
Condition person, the condition advised according to normal condition or manufacturer is carried out.Agents useful for same or instrument unreceipted production firm person, be
Can be by the commercially available conventional products bought and obtain.
A kind of medicine treating small cell lung cancer, counts by weight and includes following raw material:
Ramulus et folium taxi cuspidatae Extract 0.5-1 part, Rhizoma Paridis extract 0.2-0.6 part, Radix Ginseng extract 0.3-1.5 part, Herba Hedyotidis Diffusae
Extract 1.2-1.5 part, Semen Coicis extract 1.2-1.5 part, Herba Taraxaci extract 0.1-0.5 part, Radix Astragali extract
0.8-1.0 part, Herba Chelidonii extract 0.2-0.5 part, bletilla striata extract 0.2-0.4 part, Rhizoma Dysosmae Versipellis extract 0.2-0.5 part,
Radix Codonopsis lanceolatae extract 0.6-0.9 part, Radix Glycyrrhizae extract 0.2-0.4 part, Radix Notoginseng extract 0.1-0.4 part, Radix Angelicae Sinensis extract
0.2-0.8 part, Fructus Jujubae extract 0.8-1.0 part, Cordyceps extract 0.6-0.9 part and selenocarrageenan 0.005-0.02
Part.
The medicine of the treatment small cell lung cancer provided in the present invention, utilizes Ramulus et folium taxi cuspidatae and the significant antitumaous effect of selenium element former
Reason, the active substance Ramulus et folium taxi cuspidatae Extract grown by anti-cancer active matter and the anticancer of reasonably combined hepatocarcinoma and selenizing
Carrageenan, and scientific compatibility has the Herba Chelidonii extract of anti-cancer and kill cancer action, Rhizoma Dysosmae Versipellis extract and Radix Codonopsis lanceolatae extract, can have
The growth of cancerous cell in effect suppression minicell hepatocarcinoma, and produce certain forward improvement result to rising, cancerous cell can be induced normal
Change.Meanwhile, medicine Rhizoma Paridis extract that anti-inflammatory analgesic invigorates blood circulation, Herba Hedyotidis Diffusae extract, Herba Taraxaci extract, astragalus extraction it are equipped with
Thing, bletilla striata extract, Radix Glycyrrhizae extract, Radix Notoginseng extract, Radix Angelicae Sinensis extract and Cordyceps extract, can improve cancerous cell further
Growing environment, suppress Normocellular canceration.It addition, add again Radix Ginseng extract, Semen Coicis extract, Fructus Jujubae extract and
The nutrient substance such as Cordyceps extract, regulating human immunologic function and enhancing resistance against diseases, the regeneration of anticancer.
Ramulus et folium taxi cuspidatae Extract, effective ingredient taxine diterpene compound therein, i.e. paclitaxel, there is the antitumor of uniqueness
Effect, it is not to destroy cancerous cell, but promotes the polymerization of tubulin, stablize micro-pipe will not depolymerization, thus suppress spindle
Formation, make tumor cell be parked in the G2/M phase, until atrophy, apoptosis, death.
In the present invention, the meter typical but non-limiting content of Ramulus et folium taxi cuspidatae Extract is for example, by weight: 0.5 part,
0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part, 0.95 part or 1 part.
Rhizoma Paridis extract, nature and flavor are bitter, be slightly cold, slightly poisonous, enter Liver Channel, heat-clearing and toxic substances removing.Main Function in the present invention: heat clearing away
Removing toxic substances, reducing swelling and alleviating pain, relieve dizziness, high fever, infantile convulsions, epilepsy, etc. arresting convulsion.
In the present invention, the meter typical but non-limiting content of Rhizoma Paridis extract is for example, by weight: 0.2 part, 0.25
Part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part or 0.6 part.
Radix Ginseng extract, rich in 18 kinds of Saponins, is primarily adapted for use in coronary heart diseases and angina pectoris, bradycardia, mistake
Hurry up, ventricular premature contraction, disorder of blood pressure, neurasthenia, climacteric syndrome, overfatigue, after being ill, puerperal, postoperative physical weakness etc.
Symptom, for a long time clothes can with life lengthening, and can physical strength reinforcing, the immunologic hypofunction that treatment cancer patient causes because of radiation and chemotherapy
Deng disease, there is cold-and-heat resistent stress；There is the vigor strengthening human body surface cell simultaneously, the effects such as suppression is old and feeble.In the present invention
Main Function: strongly invigorating primordial QI, invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, increasing intelligence of calming the nerves.
In the present invention, the meter typical but non-limiting content of Radix Ginseng extract is for example, by weight: 0.3 part, 0.35
Part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part,
0.95 part, 1 part, 1.05 parts, 1.1 parts, 1.15 parts, 1.2 parts, 1.25 parts, 1.3 parts, 1.35 parts, 1.4 parts, 1.45 parts or 1.5 parts.
Herba Hedyotidis Diffusae extract, heat-clearing and toxic substances removing, dampness removing, main dyspnea and cough due to lung-heat, laryngopharynx swelling and pain, acute appendicitis, furuncle and phyma skin infection, poisonous snake sting
Wound, the puckery pain of pyretic stranguria, edema, dysentery, enteritis, jaundice due to damp-heat, cancerous protuberance.Main Function in the present invention: heat-clearing and toxic substances removing, dampness removing disappear
Carbuncle.
In the present invention, the meter typical but non-limiting content of Herba Hedyotidis Diffusae extract is for example, by weight: 1.2 parts,
1.25 parts, 1.3 parts, 1.35 parts, 1.4 parts, 1.45 parts or 1.5 parts.
Semen Coicis extract, containing rich in protein, oils and fats, vitamin, mineral and saccharide, have control the flat pox of wart,
The maintaining beauty and keeping youngs such as light speckles, beautification and white, skin moistening smoothing wrinkle, especially contained proteolytic enzyme can make skin keratin soften, dimension
Raw element E Wheat Protein；The metabolism of internal blood and moisture can be promoted, have diuresis, consumer edema etc. to act on, and can help
Help defecation, can prophylaxis of cancer.Main Function in the present invention: promoting diuresis to eliminate damp pathogen, spleen invigorating, eliminating impediment, clearing away heat and discharging pus.
In the present invention, the meter typical but non-limiting content of Semen Coicis extract is for example, by weight: 1.2 parts,
1.25 parts, 1.3 parts, 1.35 parts, 1.4 parts, 1.45 parts or 1.5 parts.
Herba Taraxaci extract, is applied to inflammation and hyperemia, and as one of maximally effective removing toxic substances medical herbs, it plays filtration
Blood flow, gallbladder, liver and nephrotoxicity element and the effect of refuse.Herba Taraxaci extract can stimulate bile secretion, and helps health to get rid of
The excessive moisture that damaged liver manufactures.Herba Taraxaci extract can recover gallbladder function, its choleretic effect for liver and gallbladder inflammation,
Remove cholelithiasis and hyperemia, and jaundice is very useful.Main Function in the present invention: heat-clearing and toxic substances removing, medicinal powder for relieving pain knot, profit
Wet.
In the present invention, the meter typical but non-limiting content of Herba Taraxaci extract is for example, by weight: 0.1 part,
0.15 part, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part or 0.5 part.
Radix Astragali extract, effective ingredient astragaloside, astragalus polysaccharides, have enhancing immunity, strengthen energy, resisting fatigue,
Mutation, protect the liver, suppress the effect of osteoclast.Astragalus polysaccharides has blood fat reducing, i.e. reduces cholesterol and triglyceride, rising
The effect of high density lipoprotein；Can prevent and treat cardiovascular and cerebrovascular disease, such as atherosclerosis, coronary artery pathological changes, week
Enclose vascular lesion and hyperlipemia etc..Astragaloside has the effect significantly reducing blood glucose, glycolated hemoglobin and urine protein,
Can reduce the AGEs in renal cortex and serum, display astragaloside has antioxidation, and has suppression to make to aldose reductase
With, also suppress proliferation of mesangial cells, alleviate the effect of renal hypertrophy.Main Function in the present invention: tonifying Qi and lifting yang, benefit are defended solid
Table, promoting pus discharge and tissue regeneration strengthening, diuretic detumescent.
In the present invention, the meter typical but non-limiting content of Radix Astragali extract is for example, by weight: 0.8 part, 0.85
Part, 0.9 part, 0.95 part or 1 part.
Herba Chelidonii extract, Chelidonine therein is a kind of mitotic poison, can make the three times higher body of ascites cells
(hypertriplokd) in, di in late period change, in significant blocking-up splitting action, fiber can be suppressed female thin
The mitosis of born of the same parents, thus delay the growth of malignant tumor.Main Function in the present invention: heat-clearing and toxic substances removing, analgesia cough-relieving.
In the present invention, the meter typical but non-limiting content of Herba Chelidonii extract is for example, by weight: 0.2 part,
0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part or 0.5 part.
Bletilla striata extract, nature and flavor are bitter, sweet, puckery, be slightly cold, and return lung, liver, stomach warp, cure mainly: astringing to arrest bleeding, detumescence and promoting granulation, are used for
Hemoptysis haematemesis, traumatic hemorrhage, sore swollen toxin, chapped skin, pulmonary tuberculosis hemoptysis, ulcer haemorrhage etc..Main work in the present invention
With: astringing to arrest bleeding, detumescence and promoting granulation.
In the present invention, the meter typical but non-limiting content of bletilla striata extract is for example, by weight: 0.2 part, 0.25
Part, 0.3 part, 0.35 part or 0.4 part.
Rhizoma Dysosmae Versipellis extract, main component Podophyllinic Acid Lactone has inhibitory action to kinds of tumors model, including acute leukemia, turns
Move lymphoma, regional nodes's tumor, adenoma and melanoma etc..Additionally, Podophyllinic Acid Lactone also has inhibitory action to human body KB cell, outward
By treatment wart disease, skin carcinoma.Main Function in the present invention: eliminating stasis and resolving masses, removing toxic substances and promoting subsidence of swelling.
In the present invention, the meter typical but non-limiting content of Rhizoma Dysosmae Versipellis extract is for example, by weight: 0.2 part, 0.25
Part, 0.3 part, 0.35 part, 0.4 part, 0.45 part or 0.5 part.
Radix Codonopsis lanceolatae extract, wherein relative molecular mass component more than 3500, have higher anti-tumor activity, and it is lived
Property composition is probably polysaccharide.Main Function in the present invention: supplementing QI and nourishing YIN, removing toxic substances and promoting subsidence of swelling, evacuation of pus, lactogenesis.
In the present invention, the meter typical but non-limiting content of Radix Codonopsis lanceolatae extract is for example, by weight: 0.6 part,
0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part or 0.9 part.
Radix Glycyrrhizae extract, invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription, for weakness of the spleen and stomach,
Fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, extremity contraction urgency pain, carbuncle sore tumefacting virus, cushion toxicity, strong.This
Main Function in bright: invigorating the spleen and replenishing QI, nourishing the lung to arrest cough, heat-clearing and toxic substances removing, the function of the mitigation property of medicine.
In the present invention, the meter typical but non-limiting content of Radix Glycyrrhizae extract is for example, by weight: 0.2 part, 0.25
Part, 0.3 part, 0.35 part or 0.4 part.
Radix Notoginseng extract, containing Saponin, predominantly ginsenoside Rb1, Rg1, Rg2 and a small amount of ginsenoside Ra, Rb2, Rb and
Re, additionally, still containing flavonoid glycoside, starch, protein, oils and fats etc..Radix Notoginseng extract has invigorating blood circulation, stops blooding, improve and strengthen arteria coronaria
Microcirculation, antiinflammatory, resisting fatigue, antitumor, analgesia, immunoregulation effect.Main Function in the present invention: blood circulation promoting and blood stasis dispelling, hemostasis,
Invigorate blood circulation analgesic therapy.
In the present invention, the meter typical but non-limiting content of Radix Notoginseng extract is for example, by weight: 0.1 part, 0.15
Part, 0.2 part, 0.25 part, 0.3 part, 0.35 part or 0.4 part.
Radix Angelicae Sinensis extract, is a kind of for replenishing and activating blood, menstruction regulating and pain relieving, loosening bowel to relieve constipation, blood deficiency and yellow complexion, dizziness cardiopalmus, the moon
Through uncomfortable, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, the plant extract of ulcer sores.This
Main Function in bright: tonifying blood and regulating menstruation, promoting blood circulation and stopping pain, loosening bowel to relieve constipation.
In the present invention, the meter typical but non-limiting content of Radix Angelicae Sinensis extract is for example, by weight: 0.2 part, 0.25
Part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 or 0.8 part.
Fructus Jujubae extract, invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind, dirty dry for insufficiency of the spleen lack of appetite, weak loose stool, married woman.In the present invention
Main Function: invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind, the mitigation property of medicine.
In the present invention, the meter typical but non-limiting content of Fructus Jujubae extract is for example, by weight: 0.8 part, 0.85
Part, 0.9 part, 0.95 part or 1 part.
Cordyceps extract, effective ingredient Cordyceps polysaccharide therein is nourishing and nourishing yin effect in rare Chinese medicine Cordyceps
Active ingredient, can regulate immune function of human body, strengthen resistance against diseases, there is anticancer and therapeutical effect, various diseases are caused
Leukocyte reduce have good auxiliary therapeutic action, also there is hypoglycemic function.Main Function in the present invention: be i.e. people
The Cordyceps militaris (L.) Link. of work cultivation, kidney tonifying tonifying the lung, hemostasis and phlegm.
In the present invention, the meter typical but non-limiting content of Cordyceps extract is for example, by weight: 0.6 part, 0.65
Part, 0.7 part, 0.75 part, 0.8 part, 0.85 part or 0.9 part.
Selenocarrageenan, is the Main Ingredients and Appearance of liver gold, the trace element of needed by human, and selenocarrageenan is hepatoma carcinoma cell
Inhibitor and therapeutic agent.Selenocarrageenan can suppress the growth of hepatoma carcinoma cell, and may under conditions of, also can make its to
Normal direction converts.Under similarity condition, selenocarrageenan grows unrestraint effect to non-cancerous cells, has certain protection on the contrary
Effect, under anoxic conditions, this protective effect is the most notable.Selenium is the trace element dominating life, and selenium element can be rapid
Increase the content of C-AAMP in cancerous cell, it is possible to stop the duplication in vivo of cell carcinogenesis and anticancer and growth, with
Time, selenium element effectively can also must reduce the activity of ATP enzyme in cancer cell tissue, the energy metabolism of anticancer.Add content
It is the organic selenium i.e. selenocarrageenan 0.01g of 3%, as the overall anticancer effect in medicine of the present invention, can play very important
Effect.
In the present invention, the meter typical but non-limiting content of selenocarrageenan is for example, by weight: 0.005 part,
0.01 part, 0.015 part or 0.02 part.
The preparation method of the medicine of a kind of above-mentioned treatment small cell lung cancer, comprises the following steps:
Weigh above-mentioned each crude drug in container, put into after mix homogeneously in granulator and pelletize, obtain described treatment little carefully
The medicine of born of the same parents' pulmonary carcinoma.
The medicine of a kind of above-mentioned treatment small cell lung cancer purposes in the medicine of preparation treatment small cell lung cancer.
Below in conjunction with embodiment 1-7 and comparative example 1-5, the present invention will be further described in detail.
The medicine of the treatment small cell lung cancer that embodiment 1-5 and comparative example 1-3 are provided, the most each crude drug preferentially selects
Extracting Chinese crude drug concentrate in order to the ratio that weight ratio is 50:1, namely extract 1kg concentrating powder with 50kg raw material is extract
It is made.Such as, weigh 50kg Ramulus et folium taxi cuspidatae, extract 1kg Ramulus et folium taxi cuspidatae Extract；Being similar to, Rhizoma Paridis extract, Radix Ginseng extract
Thing, Herba Hedyotidis Diffusae extract, Semen Coicis extract, Herba Taraxaci extract, Radix Astragali extract, Herba Chelidonii extract, bletilla striata extract,
Rhizoma Dysosmae Versipellis extract, Radix Codonopsis lanceolatae extract, Radix Glycyrrhizae extract, Radix Notoginseng extract, Radix Angelicae Sinensis extract, Fructus Jujubae extract, Cordyceps are extracted
Thing also extracts concentrate according further to the ratio of 50:1.Wherein, Ramulus et folium taxi cuspidatae Extract, is to use Taxus media former as extracting
Material, contains the cancer-resisting substance " paclitaxel " of trace in Taxus media.
Embodiment 1
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 0.5g, Rhizoma Paridis extract 0.2g, Radix Ginseng extract 0.3g, Herba Hedyotidis Diffusae extract 1.2g, Semen Coicis
Core extract 1.2g, Herba Taraxaci extract 0.1g, Radix Astragali extract 0.8g, Herba Chelidonii 0.2g, bletilla striata extract 0.2g, Rhizoma Dysosmae Versipellis carry
Take thing 0.2g, Radix Codonopsis lanceolatae extract 0.6g, Radix Glycyrrhizae extract 0.2g, Radix Notoginseng extract 0.1g, Radix Angelicae Sinensis extract 0.2g, Fructus Jujubae carry
Take thing 0.8g, Cordyceps extract 0.6g and selenocarrageenan 0.005g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 1 minute, place in electronic granulator, with 2ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Being prepared as graininess is to facilitate patient to take, and from the point of view of Chinese medicine, the most acceptable facilitates dosage form.
Embodiment 2
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 1g, Rhizoma Paridis extract 0.6g, Radix Ginseng extract 1.5g, Herba Hedyotidis Diffusae extract 1.5g, Semen Coicis
Extract 1.5g, Herba Taraxaci extract 0.5g, Radix Astragali extract 1.0g, Herba Chelidonii 0.5g, bletilla striata extract 0.4g, Rhizoma Dysosmae Versipellis are extracted
Thing 0.5g, Radix Codonopsis lanceolatae extract 0.9g, Radix Glycyrrhizae extract 0.4g, Radix Notoginseng extract 0.4g, Radix Angelicae Sinensis extract 0.8g, Fructus Jujubae extract
Thing 1.0g, Cordyceps extract 0.9g and selenocarrageenan 0.02g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 2 minutes, place in electronic granulator, with 4.5ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Embodiment 3
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 0.6g, Rhizoma Paridis extract 0.3g, Radix Ginseng extract 0.5g, Herba Hedyotidis Diffusae extract 1.3g, Semen Coicis
Core extract 1.3g, Herba Taraxaci extract 0.2g, Radix Astragali extract 0.9g, Herba Chelidonii 0.3g, bletilla striata extract 0.25g, Rhizoma Dysosmae Versipellis
Extract 0.3g, Radix Codonopsis lanceolatae extract 0.7g, Radix Glycyrrhizae extract 0.2g, Radix Notoginseng extract 0.2g, Radix Angelicae Sinensis extract 0.3g, Fructus Jujubae
Extract 0.85g, Cordyceps extract 0.7g and selenocarrageenan 0.01g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 1.5 minutes, place in electronic granulator, with 3ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Embodiment 4
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 0.9g, Rhizoma Paridis extract 0.5g, Radix Ginseng extract 1.2g, Herba Hedyotidis Diffusae extract 1.5g, Semen Coicis
Core extract 1.5g, Herba Taraxaci extract 0.4g, Radix Astragali extract 1.0g, Herba Chelidonii 0.4g, bletilla striata extract 0.35g, Rhizoma Dysosmae Versipellis
Extract 0.4g, Radix Codonopsis lanceolatae extract 0.9g, Radix Glycyrrhizae extract 0.3g, Radix Notoginseng extract 0.3g, Radix Angelicae Sinensis extract 0.7g, Fructus Jujubae
Extract 0.95g, Cordyceps extract 0.9g and selenocarrageenan 0.01g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 1.5 minutes, place in electronic granulator, with 7ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Embodiment 5
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae extracts concentrate 0.6g, Rhizoma Paridis extracts concentrate 0.4g, Radix Ginseng extracts concentrate 0.6g, Herba Hedyotidis Diffusae extracts
Concentrate 1.5g, Semen Coicis extract concentrate 1.5g, Herba Taraxaci extraction concentrate 0.3g, astragalus extraction concentrate 1.0g, bend in vain
Dish 0.3g, Pseudobulbus Bletillae (Rhizoma Bletillae) extraction concentrate 0.3g, Rhizoma Dysosmae Versipellis extraction concentrate 0.3g, Radix Codonopsis lanceolatae extraction concentrate 0.9g, Radix Glycyrrhizae are extracted dense
Contracting thing 0.2g, Radix Notoginseng extraction concentrate 0.2g, Radix Angelicae Sinensis extraction concentrate 0.6g, Fructus Jujubae extraction concentrate 0.9g, Cordyceps are extracted dense
Contracting thing 0.9g and selenocarrageenan 0.01g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 1 minute, place in electronic granulator, with 3ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 3.5g, vacuum seal.
Comparative example 1
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 0.2g, Rhizoma Paridis extract 0.1g, Radix Ginseng extract 0.1g, Herba Hedyotidis Diffusae extract 0.5g, Semen Coicis
Core extract 0.3g, Herba Taraxaci extract 0.05g, Radix Astragali extract 0.4g, Herba Chelidonii 0.1g, bletilla striata extract 0.1g, Rhizoma Dysosmae Versipellis
Extract 0.1g, Radix Codonopsis lanceolatae extract 0.4g, Radix Glycyrrhizae extract 0.1g, Radix Notoginseng extract 0.05g, Radix Angelicae Sinensis extract 0.1g, big
Fructus Jujubae extract 0.5g, Cordyceps extract 0.4g and selenocarrageenan 0.001g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 1 minute, place in electronic granulator, with 2ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Comparative example 2
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 1.5g, Rhizoma Paridis extract 1.6g, Radix Ginseng extract 0.5g, Herba Hedyotidis Diffusae extract 0.5g, Semen Coicis
Core extract 0.5g, Herba Taraxaci extract 1g, Radix Astragali extract 2.0g, Herba Chelidonii 1.5g, bletilla striata extract 1.4g, Rhizoma Dysosmae Versipellis are extracted
Thing 1.5g, Radix Codonopsis lanceolatae extract 0.9g, Radix Glycyrrhizae extract 0.4g, Radix Notoginseng extract 0.4g, Radix Angelicae Sinensis extract 0.8g, Fructus Jujubae extract
Thing 2.0g, Cordyceps extract 0.9g and selenocarrageenan 0.001g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 2 minutes, place in electronic granulator, with 4.5ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Comparative example 3
The medicine for the treatment of small cell lung cancer, including following raw material:
Ramulus et folium taxi cuspidatae Extract 0.3g, Rhizoma Paridis extract 0.2g, Radix Ginseng extract 0.1g, Herba Hedyotidis Diffusae extract 0.5g, Semen Coicis
Core extract 0.3g, Herba Taraxaci extract 0.8g, Radix Astragali extract 0.4g, Herba Chelidonii 0.1g, bletilla striata extract 0.4g, Rhizoma Dysosmae Versipellis carry
Take thing 1.5g, Radix Codonopsis lanceolatae extract 0.9g, Radix Glycyrrhizae extract 1.4g, Radix Notoginseng extract 1.4g, Radix Angelicae Sinensis extract 0.8g, Fructus Jujubae carry
Take thing 2.0g, Cordyceps extract 0.9g and selenocarrageenan 0.03g.
Said medicine is prepared by following preparation method: above-mentioned each crude drug is put into motorized agitator, up and down
Roll mix homogeneously to take out after 2 minutes, place in electronic granulator, with 4.5ml spraying purified water pelletize, in irregular particle
Shape, after dry, ultraviolet disinfection processes 2 hours, with the dosage of every pouch 4.51g, vacuum seal.
Comparative example 4
Medicine lung benefiting Qinghua granule of commercial treatment small cell lung cancer.
Comparative example 5
The medicine Shenlian granule of commercial treatment small cell lung cancer.
To be tested by the observation of curative effect of clinical treatment below, treatment small cell lung cancer that the present invention provide is expanded on further
The therapeutic effect of medicine.
Experimental data: clinical medication tracking test that 2 groups of Patients With Small Cell Carcinoma of The Lungs are carried out, often group patient 35 people.First group
The medicine that patient takes embodiment 1-5 and provided is treated, and the medicine that second group of patient takes comparative example 1-5 and provided enters
Row treatment.
First group of patient profiles's brief introduction: treat 35 examples, Huan Zhezhong, male 29 example, women 6 example in 3 years altogether.Minimal ages 29
In year, max age 67 years old, sick age is the longest 2 years, the shortest ten days, average course for the treatment of 26 days.In 35 examples, every 7 examples are 1 group, take respectively
The medicine that embodiment 1-5 is provided is treated.
Second group of patient profiles's brief introduction: treat 35 examples, Huan Zhezhong, male 25 example, women 10 example in 3 years altogether.Minimal ages
26 years old, max age 75 years old, sick age was the longest 1 year, the shortest 9 days, average course for the treatment of 30 days.In 35 examples, every 7 examples are 1 group, take respectively
The medicine provided by comparative example 1-5 is treated.
The instructions of taking of medicine: directly take, three times a day, early, middle and late 1 pouch that respectively takes, 3.7g/ bag.Positive informal dress
With 30 days (1 course for the treatment of), observe curative effect.Wherein, the patient that the medicine that taking embodiment 4 and 5 provides carries out treating is according to accordingly
The operation instruction of product is taken.
Efficacy assessment standard:
Cure: pain disappears, and clinical symptoms all eliminates；
Effective: pain has alleviated, clinical symptoms has alleviated；
Effective: pain disappears substantially, clinical symptoms substantially alleviates；
Invalid: pain is not changed in, clinical symptoms is not changed in increasing the weight of on the contrary.
Following the tracks of and observe 3 years, therapeutic effect is as shown in table 1.
The therapeutic effect of table 1 each embodiment medicine
| Effect | Cure | Cure rate | Effective | Obvious effective rate | Effectively | Effective percentage | Invalid | Inefficiency |
| First group | 13 | 37.1% | 12 | 34.3% | 9 | 25.7% | 1 | 2.9% |
| Second group | 2 | 5.7% | 4 | 11.4% | 5 | 14.3% | 24 | 68.6% |
As shown in Table 1, the drug administration of the treatment small cell lung cancer that the present invention provides is convenient, short treating period, instant effect, curative effect
Well, have no side effect.By watching 35 example Patients With Small Cell Carcinoma of The Lung in late period therapeutic outcomes, its effective percentage reaches 97.1%.
Model case is introduced:
1. Liu, man, 29 years old, Hebei province Langfang City bank clerk, coughs after coughing 6 days because of persistency in August, 2013
Sputum mixed with blood, weak, body temperature 38.6 degree, appetite declines, is diagnosed as small cell lung cancer late period (having smoking history 10 years) through hospital of city
Within 1 month, having no in the treatment of city's hospital admissions and be clearly better, discharge planning turns Beijing treatment, in JIUYUE, 2013, takes this medicine, every day 3
Secondary each 1 bag, after 10 days, clinical symptom relief, appetite increased, temperature decline 37 degree, and following the service checked after 3 months, clinical
Symptom all disappears, and expectorant inspection finds no cancerous cell, after after treatment 3 months recovery from illness again, life is normal, follows up a case by regular visits to 2 years without recurrence.
2. Korea Spro, female, 67 years old, Wuqing District, Tianjin retired worker, check through Wuqing District central hospital and make a definite diagnosis in November, 2013
Merge lymph node for small cell lung cancer, brain metastes late period, take the Chinese medicinal granule of the present invention because being afraid of that Post operation transfers, three times a day,
Each 1 bag, after taking 10 days, symptom substantially alleviates, and serve on 3 months, and clinical symptoms all disappears, and consolidates again 3 months after recovery from illness,
So far without recurrence.
3. Chen, man, 52 years old, Yishui County in Shandong Province workman, there is the smoking history of 30 years, body weight 76kg, because of cough fever one
In week, check to be small cell carcinoma in late period in central hospital of county, check in the second the People's Hospital, Jinan City, Shandong Province and be diagnosed as minicell
Pulmonary carcinoma, closely late period, take a favorable turn after being hospitalized for treatment 1 month, and rehabilitation of going home is recurred after 10 days again, through taking this medicine 7 days
After, symptom has alleviated, but body temperature is still between 38.6 38.9 degree, and after serveing on 1 month, clinical symptoms disappears substantially, following the service 3
Individual month symptomatology eliminates, after recovery from illness again after treatment 3 months so far without recurring.
4. Wang, man, 47 years old, Tangshan, Hebei Province private enterprise boss, in San Yue, 2014 Yin Duo cough, apoplexy due to phlegm had blood
Silk, has a fever many days, is diagnosed as small cell lung cancer late period at city's examination in hospital, and after taking this medicine 13 days, symptom has alleviated, food
Be intended to increased, after do not adhere to medication, stopped treatment.
Although illustrate and describing the present invention with specific embodiment, but it will be appreciated that without departing substantially from the present invention's
May be made that in the case of spirit and scope many other change and amendment.It is, therefore, intended that in the following claims
Including all such changes and modifications belonged in the scope of the invention.
Claims (10)
1. the medicine treating small cell lung cancer, it is characterised in that count by weight and include following raw material:
Ramulus et folium taxi cuspidatae Extract 0.5-1 part, Rhizoma Paridis extract 0.2-0.6 part, Radix Ginseng extract 0.3-1.5 part, Herba Hedyotidis Diffusae extract
Thing 1.2-1.5 part, Semen Coicis extract 1.2-1.5 part, Herba Taraxaci extract 0.1-0.5 part, Radix Astragali extract 0.8-1.0
Part, Herba Chelidonii extract 0.2-0.5 part, bletilla striata extract 0.2-0.4 part, Rhizoma Dysosmae Versipellis extract 0.2-0.5 part, Radix Codonopsis lanceolatae carry
Take thing 0.6-0.9 part, Radix Glycyrrhizae extract 0.2-0.4 part, Radix Notoginseng extract 0.1-0.4 part, Radix Angelicae Sinensis extract 0.2-0.8
Part, Fructus Jujubae extract 0.8-1.0 part, Cordyceps extract 0.6-0.9 part and selenocarrageenan 0.005-0.02 part.
The medicine for the treatment of small cell lung cancer the most according to claim 1, it is characterised in that meter by weight includes as follows
Raw material:
Ramulus et folium taxi cuspidatae Extract 0.6-0.9 part, Rhizoma Paridis extract 0.3-0.5 part, Radix Ginseng extract 0.5-1.2 part, Herba Hedyotidis Diffusae carry
Take thing 1.3-1.5 part, Semen Coicis extract 1.3-1.5 part, Herba Taraxaci extract 0.2-0.4 part, Radix Astragali extract 0.9-
1.0 parts, Herba Chelidonii extract 0.3-0.4 part, bletilla striata extract 0.25-0.35 part, Rhizoma Dysosmae Versipellis extract 0.3-0.4 part, mountain and sea
Spiral shell extract 0.7-0.9 part, Radix Glycyrrhizae extract 0.2-0.3 part, Radix Notoginseng extract 0.2-0.3 part, Radix Angelicae Sinensis extract 0.3-
0.7 part, Fructus Jujubae extract 0.85-0.95 part, Cordyceps extract 0.7-0.9 part and selenocarrageenan 0.01 part.
The medicine for the treatment of small cell lung cancer the most according to claim 2, it is characterised in that meter by weight includes as follows
Raw material:
Ramulus et folium taxi cuspidatae Extract 0.6 part, Rhizoma Paridis extract 0.4 part, Radix Ginseng extract 0.6 part, Herba Hedyotidis Diffusae extract 1.5 parts, Semen Coicis
Core extract 1.5 parts, Herba Taraxaci extract 0.3 part, Radix Astragali extract 1.0 parts, Herba Chelidonii extract 0.3 part, bletilla striata extract
0.3 part, Rhizoma Dysosmae Versipellis extract 0.3 part, Radix Codonopsis lanceolatae extract 0.9 part, Radix Glycyrrhizae extract 0.2 part, Radix Notoginseng extract 0.2 part, Radix Angelicae Sinensis
Extract 0.6 part, Fructus Jujubae extract 0.9 part, Cordyceps extract 0.9 part and selenocarrageenan 0.01 part.
4. according to the medicine of the treatment small cell lung cancer described in any one of claim 1-3, it is characterised in that selenocarrageenan
The content of middle organic selenium is 3wt%.
5. the preparation method of the medicine of the treatment small cell lung cancer described in an any one of claim 1-4, it is characterised in that
Comprise the following steps:
Weigh the crude drug described in any one of claim 1-4 in container, put into after mix homogeneously in granulator and pelletize, i.e.
Obtain the medicine of described treatment small cell lung cancer.
The preparation method of the medicine for the treatment of small cell lung cancer the most according to claim 5, it is characterised in that described pelletized
Journey is used spraying purified water pelletize.
The preparation method of the medicine for the treatment of small cell lung cancer the most according to claim 6, it is characterised in that after pelletization
Also include the step being dried.
The preparation method of the medicine for the treatment of small cell lung cancer the most according to claim 7, it is characterised in that after being dried
Also include the step of sterilizing.
The preparation method of the medicine for the treatment of small cell lung cancer the most according to claim 8, it is characterised in that by claim
Crude drug described in any one of 1-4 is put in electronic mixing container, rolls 1-5min, takes out and put into electronic system after mix homogeneously
In grain machine, use spraying purified water pelletize, after drying by sterilization processing, the medicine that i.e. obtain described treatment small cell lung cancer is vacuum-packed
Thing.
10. treat minicell lung according to the medicine of the treatment small cell lung cancer described in any one of claim 1-4 in preparation for one kind
Purposes in the medicine of cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610991813.0A CN106310023A (en) | 2016-11-10 | 2016-11-10 | Drug for treating small cell lung cancer, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610991813.0A CN106310023A (en) | 2016-11-10 | 2016-11-10 | Drug for treating small cell lung cancer, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106310023A true CN106310023A (en) | 2017-01-11 |
Family
ID=57816419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610991813.0A Pending CN106310023A (en) | 2016-11-10 | 2016-11-10 | Drug for treating small cell lung cancer, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106310023A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213174A (en) * | 2017-06-22 | 2017-09-29 | 江苏红豆杉药业有限公司 | A kind of pharmaceutical composition and preparation method thereof and the application in the medicine for preparing preventing and treating nerve degenerative diseases |
| CN108066743A (en) * | 2018-01-26 | 2018-05-25 | 陈保国 | A kind of Chinese medicine for the treatment of cancer and preparation method thereof |
| CN115444909A (en) * | 2022-09-15 | 2022-12-09 | 山东创时代生物工程有限公司 | Composition for improving immunity and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547525A (en) * | 2014-12-31 | 2015-04-29 | 青岛市市立医院 | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof |
-
2016
- 2016-11-10 CN CN201610991813.0A patent/CN106310023A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547525A (en) * | 2014-12-31 | 2015-04-29 | 青岛市市立医院 | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 《中国营养产品与品牌年鉴》编委会: "《中国营养产品与品牌年鉴：2005-2006版》", 31 May 2007, 新华出版社 * |
| 史敏华: "《中条山药用树木资源》", 30 September 2010, 中国林业出版社 * |
| 张霆: "小细胞肺癌局限期辩治探析", 《实用中医内科杂志》 * |
| 薛品贤: "《中医内科治法锦囊》", 31 July 2006, 广东科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213174A (en) * | 2017-06-22 | 2017-09-29 | 江苏红豆杉药业有限公司 | A kind of pharmaceutical composition and preparation method thereof and the application in the medicine for preparing preventing and treating nerve degenerative diseases |
| CN108066743A (en) * | 2018-01-26 | 2018-05-25 | 陈保国 | A kind of Chinese medicine for the treatment of cancer and preparation method thereof |
| CN115444909A (en) * | 2022-09-15 | 2022-12-09 | 山东创时代生物工程有限公司 | Composition for improving immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893722A (en) | Traditional Chinese medicinal composition for treating solar dermatitis and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN111375010A (en) | A traditional Chinese medicine composition with the functions of strengthening the body and strengthening the body, invigorating the liver and kidney, and enhancing immunity | |
| CN109010468A (en) | Antitumor Chinese and its preparation method and application based on ancient prescription Tuoli Xiaodu | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN106310023A (en) | Drug for treating small cell lung cancer, and preparation method and application thereof | |
| CN104825914A (en) | Traditional Chinese medicinal preparation for assisted treatment of breast cancer | |
| CN102178818B (en) | Traditional Chinese medicinal composition for treating breast cancer and preparation method thereof | |
| CN113813347A (en) | Preparation method and process of compound paclitaxel anti-tumor capsule tablet | |
| CN101518594A (en) | Anti-tumor immunity-enhancing traditional Chinese medicine preparation and preparation method thereof | |
| CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
| CN100409870C (en) | Chinese traditional medicinal composition for treating psoriasis | |
| CN114177261A (en) | Chinese herbal medicine formula for preventing and treating chronic diseases and resisting cancer and protecting health | |
| CN105362629A (en) | Female climacteric syndrome treatment pharmaceutical composition containing cortex eucommiae and preparation method of female climacteric syndrome treatment pharmaceutical composition containing cortex eucommiae | |
| CN105943623A (en) | Pharmaceutical composition for treating wind-heat blood-heat type pruritus cutanea | |
| CN100411663C (en) | Compound traditional Chinese medicine anti-cancer powder and preparation method thereof | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN112494614A (en) | Chinese medicinal formula for preventing and treating cancer by using combination of pawpaw and various medicines | |
| CN103933154A (en) | Traditional Chinese medicine composition for treating gout disease and preparation method thereof | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN115531488B (en) | Composition for soothing liver and strengthening spleen and being used for postoperative adjuvant therapy of breast cancer and preparation method thereof | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN107661391A (en) | Treat Yao nationality medicine external preparation of the proliferation of mammary gland and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |